Real-world Australian data on the use of cladribine in MS supports a rapid and durable disease modifying effect. The study comprised 90 patients, most on a Patient Familiarisation Program when cladribine was available during 2010-2011, with follow-up data from the MSBase registry. Most patients (78%) had relapsing-remitting MS (RRMS) as opposed to secondary progressive MS ...
Australian real world evidence supports cladribine benefits in MS
By Mardi Chapman
24 Jun 2020